NN2802
/ Novelty Nobility, Alumis
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 24, 2026
The company said Monday that China's National Medical Products Administration (NMPA) approved a clinical trial application for a phase 1b/2 clinical study of NN2802 last Thursday.
(Korea Biomedical Review)
New P1/2 trial • Chronic Spontaneous Urticaria • Immunology
1 to 1
Of
1
Go to page
1